Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
| 12/23/2021 | $25.00 | Overweight | Cantor Fitzgerald |
| 11/1/2021 | $24.00 | Outperform | SVB Leerink |
| 9/13/2021 | $30.00 | Buy | Laidlaw |
| 8/25/2021 | $26.00 | Buy | B. Riley Securities |
| 8/13/2021 | $33.00 → $30.00 | Buy | Chardan Capital |
10-Q - Vincerx Pharma, Inc. (0001796129) (Filer)
8-K - Vincerx Pharma, Inc. (0001796129) (Filer)
PRE 14A - Vincerx Pharma, Inc. (0001796129) (Filer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00
Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00
SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
Gainers Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday's after-market session. The market value of their outstanding shares is at $327.1 million. Venus Concept (NASDAQ:VERO) stock rose 10.32% to $0.95. The company's market cap stands at $6.0 million. Vincerx Pharma (NASDAQ:VINC) stock moved upwards by 5.99% to $0.73. The market value of their outstanding shares is at $21.5 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 5.82% to $0.2. The company's market cap stands at $10.9 million. Beyond Air (NASDAQ:XAIR) shares moved upwards by 5.64% to $1.31. The company's market cap stands at $60.1 million. Soligenix (NASDAQ:SNGX) stock rose 5.42% to $4.38. The m
Vincerx Pharma (NASDAQ:VINC) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.29) by 100 percent. This is a 14.71 percent increase over losses of $(0.68) per share from the same period last year.
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximum tolerated dose Expected cash runway into early 2025 PALO ALTO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quart
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology Vincerx focusing resources on continued development of VIP943 Expected cash runway into early 2025 Management to host webcast and Q&A today at 5:00 PM EDT to review pipeline and corporate updates, followed by commentary from key opinion leader Dr. M. Yair Levy PALO ALTO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting thera
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024 Expected cash runway through 2024 PALO ALTO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter of 2024 and provided an overview of its clinical programs and anticipated milestones. "During the second quarter, our team focused on execution and the c